Click on a filter below to refine your search. Remove a filter to broaden your search.
Harms include increased risks for amyloid-related imaging abnormalities (ARIA)-edema, ARIA-hemorrhage and symptomatic ARIA-edema.
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.